Presented by Nature Immunology and Nature Reviews Immunology
Produced with Support from Lonza
Originally Aired on 24 May 2016
Cancer immunotherapy – treatments that harness and enhance the powers of the immune system to fight cancer – has been hailed the biggest breakthrough in cancer research since chemotherapy.
This webinar describes some of the most promising approaches to cancer immunotherapy. These include the use of modified versions of a patient’s own T cells that are better able to target cancer cells, vaccines that boost otherwise ineffective immune responses against tumours, and antibodies that release the ‘brakes’ that the tumour environment can put on immune cells (an approach called checkpoint blockade). However, many challenges remain in translating scientific advances to clinical use. A better understanding of the complex interactions between tumours and the immune system, the varied response to therapies and the barriers to success are needed for the development of more effective cancer immunotherapies in the future.
Speakers:
- Carl June
Richard W. Vague Professor in Immunotherapy University of Pennsylvania, Philadelphia, USA - Karolina Palucka
Professor, The Jackson Laboratory, Connecticut, USA - Carl Figdor
Professor, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands - Gordon Freeman
Professor, Harvard Medical School, Massachusetts, USA
Non-viral CAR-T Cell Generation:
- Efficient transfection of primary T cells using Lonza's NucleofectorTM Technology
